MUMBAI: Natco Pharma has heralded what could become an intense pricing war in India’s pharmaceutical sector by offering its generic version of semaglutide at 90% cheaper than the original weight-loss ...

India's pharma industry is ready to flex its generics muscle as the patent for a key ingredient of blockbuster weight-loss drugs expires today. Pharmarack estimates India’s weight-loss drug market to ...

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Strides Pharma Science has agreed to acquire and in license a portfolio of branded generic medicines from Sandoz, strengthening its presence across Sub Saharan Africa. The deal, valued at about 12 ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...

A revolution is coming in the U.S. generics marketplace, one that has the potential to transform savvy organizations into engines of growth, and to end the decades-long “race to the bottom” that for ...

Feb 25 - Zydus Lifesciences (ZYDU.NS), opens new tab will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in ...